Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
Open Access
- 20 January 2018
- journal article
- research article
- Published by SAGE Publications in Bladder Cancer
- Vol. 4 (1) , 77-90
Abstract
Background: The HER family of proteins (EGFR, HER2, HER3 and HER4) have long been thought to be therapeutic targets for bladder cancer, but previous clinical trials targeting these proteins have been disappointing. Second generation agents may be more effective. Objective: The aim of this study was to evaluate responses to two second-generation irreversible tyrosine kinase inhibitors, dacomitinib and afatinib, in bladder cancer cell lines. Methods: Cell lines were characterized by targeted next generation DNA sequencing, RNA sequencing, western blotting and flow cytometry. Cell survival responses to dacomitinib or afatinib were determined using (3-[4,5-dimethylthioazol-2-yl]-2,5-diphenyl tetrazolium bromide) (MTT) or [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine methosylfate (PMS) cell survival assays. Results: Only two cell lines of 12 tested were sensitive to afatinib. Sensitivity to afatinib was significantly associated with mutation in either HER2 or HER3 ( p < 0.05). The two cell lines sensitive to afatinib were also responsive to dacomitinib ralong with an additional 4 other cell lines out of 16 tested. No characteristic was associated with dacomitinib sensitivity. Molecular profiling demonstrated that only two genes were high in both afatinib and dacomitinib sensitive cells. Further rhigher expression of RAS pathway genes was noted for dacomitinib responsive cells. Conclusions: This study confirms that cell line screening can be useful in pre-clinical evaluation of targeted small molecule inhibitors and suggests that compounds with similar structure(s) and target(s) may have distinct sensitivity profiles. Further rcombinational targeting of additional molecularly relevant pathways may be important in enhancing responses to HER targeted agents in bladder cancer.Keywords
This publication has 72 references indexed in Scilit:
- Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug RecognitionStructure, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and CufflinksNature Protocols, 2012
- Ca2+-dependent Monomer and Dimer Formation Switches CAPRI Protein between Ras GTPase-activating Protein (GAP) and RapGAP ActivitiesJournal of Biological Chemistry, 2011
- Ras in Cancer and Developmental DiseasesGenes & Cancer, 2011
- Receptor Heterodimerization: A New Mechanism for Platelet-Derived Growth Factor Induced Resistance to Anti-Epidermal Growth Factor Receptor Therapy for Bladder CancerJournal of Urology, 2011
- Emerging roles for phospholipase A2 enzymes in cancerBiochimie, 2010
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- The Human Genome Browser at UCSCGenome Research, 2002
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000